Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG FLEXTOUCH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG FLEXTOUCH.
HUMALOG MIX 75/25 vs NOVOLOG FLEXTOUCH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphasic insulin analog combining rapid-acting insulin lispro (25%) and intermediate-acting insulin lispro protamine suspension (75%). Insulin lispro lowers blood glucose by binding to insulin receptors, facilitating cellular glucose uptake, inhibiting hepatic gluconeogenesis, and promoting glycogenesis and lipogenesis.
Insulin analog with rapid onset and short duration of action; binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production.
Subcutaneous injection: 75% insulin lispro protamine suspension and 25% insulin lispro solution. Dose individualized based on glycemic goals and prior insulin regimen. Typical total daily dose: 0.5-1 unit/kg/day divided into two doses (pre-breakfast and pre-dinner).
Subcutaneous injection; typical adult dose is 0.5-1 unit/kg/day divided into multiple doses; for type 1 diabetes, administered 5-10 minutes before meals with a basal insulin; for type 2 diabetes, initial dose 4 units or 0.1-0.2 units/kg with meals.
None Documented
None Documented
Insulin lispro: 0.5-1 hour; protamine-bound fraction prolongs absorption, resulting in a biphasic profile with an effective half-life of 2-4 hours for the 75% NPL component.
1.5-2 hours (subcutaneous); terminal elimination half-life: 1.8 hours
Renal: 60-80% as unchanged drug following subcutaneous absorption; the remaining fraction undergoes hepatic metabolism and biliary/fecal excretion.
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~40%
Category C
Category C
Insulin Analog
Insulin Analog